Bioyitech Showcases at the 2025 Sports Nutrition Food Innovation Conference, Unveiling a New Strategy for Clinical-Grade Probiotic Intervention in Metabolic Diseases!
From December 18-19, 2025, the "2025 Sports and Nutrition Food Technology and Application Innovation Conference," hosted by authoritative Chinese food industry platforms FFI & "Food Wanli Xing," was grandly held in Shanghai. As a sponsor and a core speaking entity, Bioyitech made a significant appearance with its latest clinical research achievements. Dr. Xu Xianrui, the company's Vice President of R&D and a seasoned expert in the field of microecology, delivered a keynote speech titled "Clinical Probiotic Intervention for Metabolic Diseases – A New Strategy for Functional Foods," which garnered widespread attention and enthusiastic discussion among participating experts, enterprise representatives, and channel partners.
Focusing on Metabolic Health: Clinical Evidence Drives Functional Food Upgrades
Amidst the accelerating trend of "Great Health + Precision Nutrition," metabolic diseases such as hyperuricemia, diabetes, and obesity have become major challenges to national health.
While traditional medications are effective, frequent side effects have driven a surge in market demand for safe, natural, and long-term usable functional food solutions.
Dr. Xu Xianrui pointed out in his speech: "The gut is the largest immune and metabolic organ in the human body. Clinically validated functional Probiotics, intervening in metabolic disorders through multiple pathways via the 'gut-X axis' network, represent a key breakthrough for future functional food innovation."
He highlighted the clinical trial data from randomized, double-blind, controlled studies conducted in top-tier hospitals for Zhongchuang Yike's independently developed Purineed® (for lowering uric acid) series and SugaRite® (for dual reduction of blood sugar and lipids) series:
* After 8 weeks of administration, subjects in the hyperuricemia reduction group experienced an average serum uric acid decrease of 90.40 μmol/L, a reduction 3.75 times greater than the control group.
* 100% of subjects did not require emergency gout medication, with a 46.88% reduction in gout attacks and a 69.46% decrease in their duration.
* Following 90 days of intervention in the blood sugar reduction group, the intervention group's average glycosylated hemoglobin (HbA1c) decreased by 0.73%, achieving a target compliance rate of 81%, significantly outperforming the control group.
These robust clinical findings not only validate the actual efficacy of specific Probiotic Strains likeBifidobacterium animalis subsp. lactis F1-7 and Lactiplantibacillus plantarum F3-2 in metabolic regulation but also signify the advancement of China's probiotic industry from "conceptual additives" to "clinical functional foods."
As a sponsor of this conference, Bioyitech simultaneously showcased its comprehensive capabilities spanning the entire chain from upstream microbial strain R&D, midstream intelligent manufacturing, to downstream application implementation :
* Possessing an in-house microbial strain library of over 6,000 strains, with more than 120 strains having clear functional labels;
* Holding 14 patents related to microbial strains and publishing over 60 SCI papers;
* Our Shanghai Fengxian production base meets pharmaceutical-grade Class 100 cleanroom standards and is equipped with 5 fully automated intelligent production lines;
* Having established the Zhongchuang Metabolism Series, a matrix of nine major functional categories, covering popular market segments such as reduce blood glucose and blood lipids, blood glucose control, immune regulation, liver protection and alcohol detoxification, and mood/sleep support.
* Furthermore, the company has co-established the Bioyitech Microecology Research Institute with universities including Ocean University of China, Zhejiang University, Harbin Institute of Technology, and Zhejiang Chinese Medical University, continuously promoting integrated innovation across "industry, academia, research, medicine, inspection, and application."
During this conference, Bioyitech through introductions from the organizers, engaged in discussions with numerous brands, distributors, and research institutions. With multiple international certifications such as GFSI, FDA, HALAL, and export filing, the company is accelerating its expansion into overseas markets including North America, Southeast Asia, and Western Asia, dedicated to doing microecology well, connecting to great health, and bringing Chinese probiotics to the world.